Skip to main content
Fig. 3 | Molecular Medicine

Fig. 3

From: Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia

Fig. 3

Ibrutinib reduces inflammatory myeloid cell responses in the lung during ceftriaxone-treated pneumococcal pneumonia. Mice were infected intranasally with S.pneumoniae bacteria and treated 24 h later with ceftriaxone. Concomitant with ceftriaxone and 12 h later, vehicle or ibrutinib was given and mice were sacrificed 48 h after induction of infection. Mice sacrificed at 24 h (n = 4) after inoculation with S. pneumoniae without additional treatment served as control. a Colony forming units (CFU) in bronchoalveolar lavage fluid (BALF), spleen and blood. b Total cells. (c, left panel) polymorphonuclear cells (PMN), (d) monocytes and (e) alveolar macrophags (AM) in BALF depicted as 103cells/mL. (c, right panel) percentage of LY-6G positive lung surface as a measure for total lung PMN numbers. f CD11c expression (geometric mean) on BALF AM. g CD11b expression (geometric mean) on BALF PMN. h concentrations myeloperoxidase (MPO) and elastase in BALF. i Concentrations of total protein and immunoglobulin (Ig) M in BALF as a measure for plasma leakage into the lung. j Lung pathology score. Data are represented as mean and SD. *p < 0.05, **p < 0.01, ***p < 0.001 (Kruskal-Wallis 1-way analysis of variance test followed by Mann-Whitney U-test). Data represent results from a single experiment

Back to article page